Upgrade to SI Premium - Free Trial

Biogen (BIIB) Survey Data Conflicts with Bullish View, Piper Sandler Beginning to Get Concerned

October 13, 2021 10:06 AM
Piper Sandler analyst Christopher Raymond reiterated an Overweight rating and $460.00 price target on Biogen (NASDAQ: BIIB) after conducting a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot Comments

Next Articles